Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Vepdegestrant in Participants With Hepatic Impairment
NCT07231991Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of vepdegestrant in breast cancer (3 arms), sponsored by Pfizer. Primary endpoints: Maximum observed concentration at 216 hours and Area under the curve from time zero to extrapolated infinite time at 216 hours. Started Nov 2025; status: recruiting.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07231991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231991.